Ascendis (ASND) Q3 2026 Earnings Call Transcript

Ascendis (ASND) reported Q3 2026 product revenue of €366 million, up 89% YoY. Key drivers: growth in existing products (Yorvipath, Yuvivel, Skytrofa), indication expansions, and new products. Yorvipath revenue was €291 million, up 103% YoY. Yuvivel and Skytrofa also showed strong demand. The company aims for €5 billion in annual revenue by 2030.

Original reporting
Published Nov 12, 2026, 3:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ascendis (ASND) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ASNDBullishHigh
01

Why it matters

The strong revenue growth and pipeline progress provide a fresh catalyst for the stock.

02

Market read

First report of Q3 earnings with significant revenue growth, offering actionable insight for traders.

03

What to watch

Potential regulatory delays for upcoming label extensions could temper growth.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Ascendis Pharma held its Q3 2026 earnings call, presenting revenue and pipeline updates.

Company-level read

Ticker impact

$ASNDBullishHigh confidence
Context

Q3 2026 product revenue of €366 million, up 89% year over year, indicating strong growth.

Expected impact

likely upward pressure as market prices in strong revenue growth

Evidence & confidence

Revenue growth far exceeds prior year and quarter, providing fresh positive catalyst.

Market effects

Biopharma sector may see broader optimism from Ascendis' growth.

European markets could benefit from the strong Euro‑denominated revenue.

Highlights demand for rare‑disease therapies worldwide.

Counterpoint

If guidance falls short of expectations, the stock could face a pullback despite revenue beat.

Key entities

  • Ascendis Pharma

    US‑listed biopharma company (ASND).

Related articles

$ASNDMed

TD Cowen raises Ascendis Pharma stock price target on revenue beat

TD Cowen raised its price target for Ascendis Pharma (ASND) to $352, citing strong Q3 revenue beats across its products. Revenue grew 86% YoY with a 92% gross margin. The company reaffirmed long-term revenue targets of €5B by 2030 and €10B by 2035. ASND stock trades near its 52-week high at $266.31. Other analysts also raised targets and maintained positive ratings.

$ASNDMedAI 8/10

Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH

Ascendis Pharma AS reported Q3 2026 revenue up 89%, driven by YORVIPATH. CEO Jan Mikkelsen discussed new therapeutic areas, ex-US growth, and YUVIWEL's potential. The company expects steady US uptake and EUR5B 2030 sales. CFO Scott Smith noted EUR330M spent on share buybacks, with EUR600M operating cash flow guided for 2026. Margins improved to mid-40s, with no major commercial infrastructure changes expected.

$ASNDHighAI 8/10

Ascendis Pharma earnings analysis: questions answered and next catalysts

Ascendis Pharma (ASND) reported Q3 2026 earnings, beating revenue and EPS estimates. Shares rose 2.93% to $266.88. Key drugs showed strong demand, and the company increased its cash flow outlook. Management addressed growth, funding, and competition. Next catalysts include regulatory decisions, clinical trials, and market expansion. Analysts debate valuation and future growth prospects.

HighAI 8/10

Why is Ascendis Pharma stock climbing today?

Ascendis Pharma's stock rose 0.5% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of €1.08 vs. €0.80 and revenue of €369.7M vs. €363.0M. YORVIPATH sales grew 103% YoY to €291M. The company also repurchased 2M shares for $459M and received positive EU regulatory opinions for TransCon CNP.